Vaxcyte (PCVX) investor relations material

Mission and platform overview

• Focused on engineering high-fidelity vaccines to protect against bacterial diseases globally.

• Utilizes a proprietary cell-free protein synthesis platform (XpressCF) enabling rapid, flexible, and scalable vaccine development.

• Platform allows site-specific conjugation, producing carrier-sparing conjugates that enhance immune responses and enable broader-spectrum vaccines.

Pneumococcal conjugate vaccine (PCV) franchise

• VAX-31 is the broadest-spectrum PCV in clinical development, designed to cover ~95% of invasive pneumococcal disease (IPD) in U.S. adults ≥50 years.

• VAX-24 and VAX-31 target both adult and pediatric populations, with VAX-31 also aiming for ~92% IPD and ~96% acute otitis media coverage in children.

• Phase 3 OPUS program for VAX-31 includes pivotal noninferiority and real-world use trials; enrollment completed in key studies.

• VAX-31 and VAX-24 demonstrate robust immunogenicity and safety profiles, with little evidence of carrier suppression.

Market opportunity and adoption drivers

• Global pneumococcal vaccine market is ~$8B, with significant growth expected from expanded adult recommendations and broader-spectrum vaccines.

• Broader serotype and disease coverage is the primary driver of adoption among healthcare providers and payers.

• Premium pricing and rapid uptake are supported by clinical guidelines and demonstrated advantages over existing vaccines.